R&D channel feed

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Last year
Cell/Gene Tx
FDA+

Good clin­i­cal prac­tices: FDA opens up­dat­ed ICH draft guid­ance for com­ments

Last year

Arv­inas’ prostate can­cer treat­ment shows hints of sig­nal — but how many pa­tients will it work for?

2 years ago

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

2 years ago
Cell/Gene Tx

Ak­ili re­leas­es non-pre­scrip­tion ver­sion of video game dig­i­tal ther­a­py for adults with AD­HD

2 years ago

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

2 years ago
Deals
Cell/Gene Tx

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

3 years ago

Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

3 years ago
Financing

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

3 years ago

Ear­ly da­ta show Bicara’s bis­pe­cif­ic helps shrink head and neck can­cers when com­bined with Keytru­da: #AS­CO23

3 years ago

Bio­gen cuts PhI­II Parkin­son’s pro­gram over ‘long time­line’ 

3 years ago

Bellerophon's stock tanks as in­haled drug-de­vice fails to re­deem it­self in new PhI­II af­ter pre­vi­ous flops

3 years ago

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

3 years ago

FDA lifts clin­i­cal hold on Foghorn’s study for blood and bone mar­row can­cer treat­ment

3 years ago

As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

3 years ago

Mod­er­na, Mer­ck say their can­cer vac­cine re­duces metas­tases by 65% in PhII study of high-risk melanoma: #AS­CO23

3 years ago

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

3 years ago
Cell/Gene Tx

J&J’s blad­der can­cer drug Balver­sa cuts the risk of death in fol­low-up tri­al: #AS­CO23

3 years ago

As­traZeneca moves ear­ly for full ap­proval with an­ti­co­ag­u­lant re­ver­sal drug An­dexxa af­ter pos­i­tive PhIV da­ta

3 years ago
FDA+

Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

3 years ago

Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

3 years ago

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

3 years ago

Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

3 years ago

Keytru­da be­fore and af­ter lung can­cer surgery cuts re­lapse risk by 42%, but doesn’t im­prove sur­vival: #AS­CO23

3 years ago
First page Previous page 83848586878889 Next page Last page
A service from the Financial Times